Trabectedin in advanced synovial sarcomas

A multicenter retrospective study from four European institutions and the Italian Rare Cancer Network

Roberta Sanfilippo, Palma Dileo, Jean Yves Blay, Anastasia Constantinidou, Axel Le Cesne, Charlotte Benson, Laura Vizzini, Marianna Contu, Giacomo G. Baldi, Angelo P. Dei Tos, Paolo G. Casali

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Treatment options for patients with metastatic synovial sarcoma are limited. Over recent years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was to study the efficacy of trabectedin in the subgroup of synovial sarcomas. A retrospective analysis was carried out on patients with advanced synovial sarcoma treated with trabectedin at four European reference sarcoma centers and within the Italian Rare Cancer Network between 2000 and 2013. Radiological response, progression-free, and overall survival, as well as serious and unexpected adverse events were retrospectively assessed. Sixty-one patients with metastatic synovial sarcoma were identified. The median number of previous chemotherapy regimens was 2 (range 1-6). Nine patients had a partial response, in addition to two minor responses, and 19 patients had stable disease, for an overall response rate of 15% and a tumor control rate of 50%. The median progression-free survival was 3 months, with 23% of patients free from progression at 6 months. The median progression-free survival in responding patients was 7 months. Trabectedin is a therapeutic option for palliative treatment of a subset of patients with metastatic synovial sarcoma.

Original languageEnglish
Pages (from-to)678-681
Number of pages4
JournalAnti-Cancer Drugs
Volume26
Issue number6
DOIs
Publication statusPublished - Jun 9 2015

Fingerprint

trabectedin
Synovial Sarcoma
Multicenter Studies
Retrospective Studies
Neoplasms
Disease-Free Survival
Sarcoma
Ifosfamide
Anthracyclines
Proxy
Palliative Care

Keywords

  • chemotherapy
  • soft tissue sarcoma
  • synovial sarcoma
  • trabectedin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Trabectedin in advanced synovial sarcomas : A multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. / Sanfilippo, Roberta; Dileo, Palma; Blay, Jean Yves; Constantinidou, Anastasia; Le Cesne, Axel; Benson, Charlotte; Vizzini, Laura; Contu, Marianna; Baldi, Giacomo G.; Dei Tos, Angelo P.; Casali, Paolo G.

In: Anti-Cancer Drugs, Vol. 26, No. 6, 09.06.2015, p. 678-681.

Research output: Contribution to journalArticle

Sanfilippo, Roberta ; Dileo, Palma ; Blay, Jean Yves ; Constantinidou, Anastasia ; Le Cesne, Axel ; Benson, Charlotte ; Vizzini, Laura ; Contu, Marianna ; Baldi, Giacomo G. ; Dei Tos, Angelo P. ; Casali, Paolo G. / Trabectedin in advanced synovial sarcomas : A multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. In: Anti-Cancer Drugs. 2015 ; Vol. 26, No. 6. pp. 678-681.
@article{701edd99537a43f1974e2c3fc4f6224f,
title = "Trabectedin in advanced synovial sarcomas: A multicenter retrospective study from four European institutions and the Italian Rare Cancer Network",
abstract = "Treatment options for patients with metastatic synovial sarcoma are limited. Over recent years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was to study the efficacy of trabectedin in the subgroup of synovial sarcomas. A retrospective analysis was carried out on patients with advanced synovial sarcoma treated with trabectedin at four European reference sarcoma centers and within the Italian Rare Cancer Network between 2000 and 2013. Radiological response, progression-free, and overall survival, as well as serious and unexpected adverse events were retrospectively assessed. Sixty-one patients with metastatic synovial sarcoma were identified. The median number of previous chemotherapy regimens was 2 (range 1-6). Nine patients had a partial response, in addition to two minor responses, and 19 patients had stable disease, for an overall response rate of 15{\%} and a tumor control rate of 50{\%}. The median progression-free survival was 3 months, with 23{\%} of patients free from progression at 6 months. The median progression-free survival in responding patients was 7 months. Trabectedin is a therapeutic option for palliative treatment of a subset of patients with metastatic synovial sarcoma.",
keywords = "chemotherapy, soft tissue sarcoma, synovial sarcoma, trabectedin",
author = "Roberta Sanfilippo and Palma Dileo and Blay, {Jean Yves} and Anastasia Constantinidou and {Le Cesne}, Axel and Charlotte Benson and Laura Vizzini and Marianna Contu and Baldi, {Giacomo G.} and {Dei Tos}, {Angelo P.} and Casali, {Paolo G.}",
year = "2015",
month = "6",
day = "9",
doi = "10.1097/CAD.0000000000000228",
language = "English",
volume = "26",
pages = "678--681",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Trabectedin in advanced synovial sarcomas

T2 - A multicenter retrospective study from four European institutions and the Italian Rare Cancer Network

AU - Sanfilippo, Roberta

AU - Dileo, Palma

AU - Blay, Jean Yves

AU - Constantinidou, Anastasia

AU - Le Cesne, Axel

AU - Benson, Charlotte

AU - Vizzini, Laura

AU - Contu, Marianna

AU - Baldi, Giacomo G.

AU - Dei Tos, Angelo P.

AU - Casali, Paolo G.

PY - 2015/6/9

Y1 - 2015/6/9

N2 - Treatment options for patients with metastatic synovial sarcoma are limited. Over recent years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was to study the efficacy of trabectedin in the subgroup of synovial sarcomas. A retrospective analysis was carried out on patients with advanced synovial sarcoma treated with trabectedin at four European reference sarcoma centers and within the Italian Rare Cancer Network between 2000 and 2013. Radiological response, progression-free, and overall survival, as well as serious and unexpected adverse events were retrospectively assessed. Sixty-one patients with metastatic synovial sarcoma were identified. The median number of previous chemotherapy regimens was 2 (range 1-6). Nine patients had a partial response, in addition to two minor responses, and 19 patients had stable disease, for an overall response rate of 15% and a tumor control rate of 50%. The median progression-free survival was 3 months, with 23% of patients free from progression at 6 months. The median progression-free survival in responding patients was 7 months. Trabectedin is a therapeutic option for palliative treatment of a subset of patients with metastatic synovial sarcoma.

AB - Treatment options for patients with metastatic synovial sarcoma are limited. Over recent years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was to study the efficacy of trabectedin in the subgroup of synovial sarcomas. A retrospective analysis was carried out on patients with advanced synovial sarcoma treated with trabectedin at four European reference sarcoma centers and within the Italian Rare Cancer Network between 2000 and 2013. Radiological response, progression-free, and overall survival, as well as serious and unexpected adverse events were retrospectively assessed. Sixty-one patients with metastatic synovial sarcoma were identified. The median number of previous chemotherapy regimens was 2 (range 1-6). Nine patients had a partial response, in addition to two minor responses, and 19 patients had stable disease, for an overall response rate of 15% and a tumor control rate of 50%. The median progression-free survival was 3 months, with 23% of patients free from progression at 6 months. The median progression-free survival in responding patients was 7 months. Trabectedin is a therapeutic option for palliative treatment of a subset of patients with metastatic synovial sarcoma.

KW - chemotherapy

KW - soft tissue sarcoma

KW - synovial sarcoma

KW - trabectedin

UR - http://www.scopus.com/inward/record.url?scp=84930590633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930590633&partnerID=8YFLogxK

U2 - 10.1097/CAD.0000000000000228

DO - 10.1097/CAD.0000000000000228

M3 - Article

VL - 26

SP - 678

EP - 681

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 6

ER -